DNBC-FINANCIAL-GROUP
13.4.2022 18:35:14 CEST | Business Wire | Press release
To make a big achievement in today's global economy and win sales against overseas competition, businesses must provide their clients with appealing sales conditions accompanied by proper international business payments mechanisms. The most common way to pay international business invoices is via bank wire transfer or credit unions, yet the currency exchange rate is high.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220413005543/en/
Another option is believed to be one of the best international payment solutions for business is via online payment providers. DNBC now will show you 5 reasons to make international business payments via business account to avoid losing potential customers to competition by failing to consider other payment choices.
1. Being Transparent
Businessmen are concerned they would be charged high fees if they want to make international business payments. Making cross-border payments may be complicated and costly due to hidden fees and confusing exchange rate calculations. Make sure you always know the exchange rates and costs associated with money transfer services prior to making a transaction.
2. Transferring around the world in multiple currencies
Cash is still preferred when making purchases, but not everyone is willing to accept it, especially when making international business payments. Paying mortgages and other invoices in a foreign nation is a tremendous demand for any businessman.
At DNBC Financial Group
, we enable SWIFT and SEPA transfers to 170 countries and territories worldwide, providing our clients with a range of transfer alternatives at the lowest possible rate and with the least amount of wait time.
3. Organizing Your Business Records
Having a business checking account to make international business payments is a great idea for businessmen to manage their firm. The account may store both receipts and expenditure checks, which helps you keep track of costs, check up on spending, avoid overspending and calculate profit margin in an easy way.
With DNBCnet Mobile App
, you may check the balance on your payment card at any time and from any location through DNBCnet, SMS Banking, or any ATM. Moreover, we also support exporting e-statements of your transactions over the course of a month or many months.
4. Transferring Limits
The maximum amount per transaction is one of the top requirements for creating a business checking account. Some suppliers need a minimum payment, while others have no restrictions at all. Finding a source or provider that can consistently meet your company's demands is critical.
Here at DNBC, the transaction limit can come up to 500 000 EUR/ day for business accounts.
5. Transferring Speed
Since making international business payments via bank transfer requires the person to visit the physical bank and fill out paperwork, it is considered to be extremely time-consuming. Or, when you need an instant transfer, credit unions can be the best bet. However, fees for these services are charged higher than other methods!
Online payment providers like DNBC provide lower transaction costs and the same advantages. It takes one to three business days to process most currencies, but some currencies may take longer. Here is DNBC Financial Group's average transaction speed:
- SWIFT services for international transfer: 02-05 business days
- SEPA for Eurozone transfer: 01-02 business days
Make International Payments Via Business Accounts With DNBC
DNBC Financial Group strives to become the best business account for international payments. We offer full online banking experience, money transactions in over 170 countries with multiple currencies, and are always ready to support you 24/7. Find out how DNBC can help you make international payments better.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220413005543/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer samarbejdsfirmaet TechSparq25.10.2026 06:09:00 CET | Pressemeddelelse
Andersen Consulting udvider sine kompetencer inden for teknologi og forretningstransformation gennem en samarbejdsaftale med TechSparq, en amerikansk virksomhed, der kombinerer strategi, commerce engineering og ai med praktisk implementering. TechSparq er et digitalt konsulenthus, der tilbyder strategi- og rådgivningstjenester, commerce engineering samt tjenester inden for ai og agentbaseret handel til virksomheder inden for detailhandel og forbrugsgoder, luksus og mode samt e-handel og direkte salg til forbrugere. Virksomheden har hovedkontor i Oregon og kombinerer strategisk planlægning med praktisk implementering for at hjælpe kunderne med at udvikle deres digitale initiativer, kundeoplevelse og driftsmodeller. "Vi etablerede vores virksomhed for at bygge bro mellem dem, der udvikler strategien, og dem, der har ansvaret for at føre den ud i livet," udtalte Dedrick Boyd, stifter af og administrerende direktør for TechSparq. "Vores samarbejde med Andersen Consulting giver os mulighed
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
